GlassScriptPhysician profile
Katherine Windrim
NPI 1508234162
$11,462.12
in general payments reported to CMS, 2019-2025
23 companies · $3,891 in 2025
The $3,891 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $517 · 2022: $1,490 · 2023: $2,614 · 2024: $2,949 · 2025: $3,891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,294 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,294.29 |
| Education | $160.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,290.15 | 2022-2025 | Caplyta |
| Alkermes, INC. | $1,266.89 | 2021-2025 | Aristada, Lybalvi |
| Corium, LLC | $967.57 | 2022-2025 | Azstarys |
| Abbvie INC. | $926.92 | 2021-2025 | |
| Axsome Therapeutics, INC. | $755.56 | 2022-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $723.06 | 2024-2025 | Fanapt |
| Lundbeck LLC | $689.82 | 2021-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $651.93 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $614.33 | 2021-2025 | Spravato, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $602.39 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Almatica Pharma LLC | $501.15 | 2023-2025 | Loreev Xr |
| Neurocrine Biosciences, INC. | $472.89 | 2021-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $346.26 | 2022-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $145.07 | 2022-2024 | Trintellix |
| Idorsia Pharmaceuticals US INC | $110.68 | 2022-2023 | Quviviq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $79.85 | 2024-2025 | Xelstrym |
| E.R. Squibb & Sons, L.L.C. | $72.54 | 2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $56.09 | 2024 | |
| Indivior INC. | $52.45 | 2023 | Perseris |
| Sunovion Pharmaceuticals INC. | $40.65 | 2021 | |
| Collegium Pharmaceutical, INC. | $40.01 | 2025 | Jornay Pm |
| Owp Pharmaceuticals, INC. | $28.99 | 2023-2025 | Subvenite, Lamotrigine |
| Tempus Ai, INC | $26.87 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Windrim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.